BD Life Sciences – Biosciences ‘Advances in Clinical Flow Cytometry’
To enable knowledge-sharing of best practices and technological advancement in clinical applications of flow cytometry, BD Life Sciences-Biosciences, a segment of BD (Becton, Dickinson and Company), recently organised the ‘Advances in Clinical Flow Cytometry’ (ACFC) multi-city roadshow for clinicians and physicians.
Organised in Bengaluru, Dhaka, Lucknow and Mumbai, each of the ACFC events also enabled discussions by experts from the clinical fraternity on critical aspects of clinical diagnostics, including Standardization, Performance, Accreditation, Automation and Collaboration.
Flow Cytometry is used to sort, separate and examine microscopic particles, such as cells and chromosomes. It plays a vital role in clinical diagnostics and research. BD offers a growing portfolio of flow cytometry instruments for Leukemia/Lymphoma phenotyping, stem cell research, immunology, and CD4 testing.
Commenting on the ACFC initiative, Pavan Mocherla, Managing Director, BD India/South Asia, said, “Over the years, flow cytometry has proven to be an invaluable asset in several clinical applications and plays an important role in clinical diagnostics and research. Cognizant of this and aligned with our purpose of Advancing the World of Health, BD has been organising the Advances in Clinical Flow Cytometry (ACFC) knowledge sharing sessions for clinicians and haematologists since 2018. Our objective is to provide a platform to discuss new processes and leading technology best practices to enable better patient outcomes, and I am happy to share that we engage with more than 150 leading clinicians and medical professionals annually under this platform.“
At this edition of ACFC, eminent speakers from the clinical fraternity discussed several clinical applications and the importance of quality. Key highlights of the discussions included case studies on Leukemia and Lymphoma and Minimal Residual Disease, amongst others. Deliberation of standard operating protocols, accuracy and standardisation of flow cytometry assays. Thirdly, the importance of quality and standardisation of assays in clinical flow cytometry.
Commending the ACFC initiative, Dr Arun Kumar Arunachalam – MD, PDF, Assistant Professor, Department of Hematology Christian Medical College, Vellore, said, “Advances in clinical flow cytometry is a wonderful initiative by BD towards bringing people together who are involved in clinical flow cytometry in the country.”
Present at the event, Dr Ananth Vikas Jayaram – Pathologist, Neuberg Anand Reference Laboratory, Bengaluru, said, “The lengthy discussions on assay parameters, troubleshooting, the utility of different markers and the debate on standardisation were all testament to the quality of the program and the interest it generated among attendees. We look forward to many more such meetings in the future.”
BD is one of the largest global medical technology companies globally and is advancing the world of health by improving medical discovery, diagnostics, and the delivery of care. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety, and expand access to health care.